![W. Scott Willett](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
W. Scott Willett
Corporate Officer/Principal presso Promedior, Inc.
Posizioni attive di W. Scott Willett
Società | Posizione | Inizio | Fine |
---|---|---|---|
Promedior, Inc.
![]() Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Corporate Officer/Principal | 01/01/2007 | - |
Storia della carriera di W. Scott Willett
Precedenti posizioni note di W. Scott Willett
Società | Posizione | Inizio | Fine |
---|---|---|---|
BOXLIGHT CORPORATION | Vendite & Marketing | 18/09/2020 | - |
AMGEN INC. | Corporate Officer/Principal | - | - |
The University of Colorado | Corporate Officer/Principal | - | - |
Neose Technologies, Inc.
![]() Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Direttore/Membro del Consiglio | - | 23/02/2011 |
Corporate Officer/Principal | 23/02/2011 | - |
Formazione di W. Scott Willett
University of Michigan | Undergraduate Degree |
The University of California, San Francisco | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Corporate Officer/Principal | 4 |
Director/Board Member | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 4 |
Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
AMGEN INC. | Health Technology |
BOXLIGHT CORPORATION | Electronic Technology |
Aziende private | 2 |
---|---|
Promedior, Inc.
![]() Promedior, Inc. Medical SpecialtiesHealth Technology Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA. | Health Technology |
Neose Technologies, Inc.
![]() Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
- Borsa valori
- Insiders
- W. Scott Willett
- Esperienza